Risdiplam
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Risdiplam: From Spinal Muscular Atrophy to Acne
One-Sentence Summary
Risdiplam is an SMN2 pre-mRNA splicing modulator originally developed for spinal muscular atrophy (SMA). The TxGNN model predicts it may be effective for Acne, but this prediction is currently supported by 0 clinical trials and 0 publications, and no plausible biological mechanism linking the two conditions has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Spinal muscular atrophy (SMA) (from repurposing rationale narrative; not confirmed in structured regulatory data — original_indications field is empty) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for risdiplam is not available in this evidence pack (marked as a data gap). Based on the repurposing rationale provided, risdiplam is known as an SMN2 pre-mRNA splicing modulator, used in SMA to increase retention of SMN2 exon 7 and thereby raise functional SMN protein expression.
There is no established pathway connecting SMN2 splicing modulation to acne pathophysiology (e.g., sebaceous gland regulation, TLR2/4 inflammatory signaling, androgen metabolism, or C. acnes suppression). SMA and acne are unrelated in both target organ system and disease mechanism.
This prediction currently rests solely on the TxGNN model's statistical score, with no supporting mechanistic, preclinical, or clinical evidence. It should be treated as a low-confidence hypothesis requiring biological validation before any further evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Risdiplam is not currently marketed in New Zealand; no authorizations are on record (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA package insert warnings/contraindications data is marked as a Blocking data gap — required before any Stage 1 safety assessment can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 (model prediction only), with no clinical trials, literature, or identified mechanistic link supporting acne as an indication for risdiplam. Foundational drug data (original indication, MOA, TFDA safety labeling) also remain incomplete.
To proceed, the following is needed:
- Confirmed original indication and mechanism of action (currently data gaps)
- TFDA/regulatory package insert warnings and contraindications (Blocking gap, DG001)
- Preclinical or mechanistic rationale connecting SMN2 splicing modulation to dermatological/acne pathways
- At minimum, exploratory or observational clinical evidence before advancing past S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.